a DB = double-blind, DM = diabetes mellitus, HbA 1c = glycosylated hemoglobin, MC = multicenter, NPH = isophane insulin human, NR = not recorded, OL = open-label, PG = parallel-group, R = randomized.
Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...
Various types of insulin are commonly used by people with type 1 and 1.5 diabetes. They differ in how quickly they start to work and how long their effects last: Diet and exercise can help some ...
Learning a pet has diabetes can be a shock. Sadly, about 20% of diabetic cats and dogs are euthanized within a year of ...
Admelog has also been approved in Europe as a biosimilar under the name Insulin ... its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba ...
The long-acting insulin, which will treat millions of diabetes patients, is the result of a 2022 partnership between Egyptian firm Eva Pharma and global pharmaceutical giant Eli Lilly and Company.
Summary: Insulin detemir is a long-acting, neutral, and soluble insulin analogue with a lower within-subject variability of fasting plasma glucose levels than isophane insulin human (NPH insulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results